about
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.A review of excision repair cross-complementation group 1 in colorectal cancer.A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression.The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates.Influence of sex on the survival of patients with esophageal cancer.Molecular pathways: Estrogen pathway in colorectal cancer.Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.Molecular markers in the treatment of metastatic colorectal cancer.Predictive molecular classifiers in colorectal cancer.Cancer dormancy: a model of early dissemination and late cancer recurrence.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.Novel opportunities for thymidylate metabolism as a therapeutic target.Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis.PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle.The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.Common cancer stem cell gene variants predict colon cancer recurrence."HER majesty's a pretty nice girl but she changes from day to day".KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
P50
Q30931932-FBB136DD-12BD-4F14-824B-673E1012D5AFQ34209365-9A6F363A-5E0F-4E57-ABA3-560EECA641DBQ34987904-9890A73B-2426-41C5-A49B-70C4C62810F1Q35055207-CF7657EA-EB69-4238-AA7D-A7AFA014141DQ35224310-9A790699-416B-4CAE-A1A3-0790DE8580B6Q36097512-8AA8E9D8-55E0-4EC1-9652-9BC15A15F045Q37332776-F1EFA2F1-B4D9-43C9-8905-069C1EF47EBAQ37332789-B56EA23E-B46D-40DC-8E81-43781CFABFAFQ37623740-F65B1085-0EFB-4F72-B879-CC4333668C94Q37762949-9CF6337E-7960-413A-95A4-9DE075A629CDQ37910398-3C39E1AC-6792-4C43-ABC2-4E8013EF938BQ37966713-01712F94-EF57-410F-9155-855A2855AD10Q39214195-36DB3E47-4245-43A6-9A88-0DFFAEDCB136Q39677535-D8E6BE8A-E609-4F37-AECC-9C82BAC2F6D4Q39940022-06F607A2-EF70-4B89-84F7-421F86BC4DB6Q41714515-E55408A8-8BCB-4398-8C1D-70879B5D33D2Q42181728-952A63A5-5F27-4F7E-9685-3C3FC731A32CQ42487948-4A63E60B-0E89-4749-93BB-30BADB8E7FF6Q44659750-5A0E5961-B313-40CE-A32B-96DD61A4BDE7Q45080019-BDD9A7F8-E212-4474-9288-7C6E4136A1A6Q45983305-8113F2DE-6D8B-4B3F-B2DE-54EC5B5E9683Q46406521-062E051E-F473-4575-97C4-341D4802408AQ46776621-07799CF2-2862-4BE8-944F-8F84C2C97D82Q51008490-E776B98D-C8E5-4E28-AB6F-698C50583ABDQ54540240-F99BEFEA-67B2-4B7A-AF0C-51F478F5DA0CQ83324588-7FED2409-42EC-4A53-9BB9-3AC6049EEE99
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Melissa J LaBonte
@en
Melissa J LaBonte
@nl
type
label
Melissa J LaBonte
@en
Melissa J LaBonte
@nl
prefLabel
Melissa J LaBonte
@en
Melissa J LaBonte
@nl
P31
P496
0000-0002-0354-413X